logo

EVIDENCE • EXPERIENCE • OUTCOMES

INTELLIGENCE BYMDReviewer
Home
About
Peptides
Contact
Back
Pre-approval drug. This compound is in active clinical trials and is not yet FDA-approved. Information here is for situational awareness only and should not be used to inform prescribing decisions.
  • No Preview Available

Cagrilintide

PipelinePhase 3PeptideInvestigationalNot approved yet. Being tested in human clinical trials.
Sponsor:
Novo Nordisk A/S
Active US trials:
7
Earliest primary completion:
Oct 30, 2024
👋

No perspectives yet — be the first!

100% anonymous · Verified U.S. prescribers only

(no name, NPI, or practice ever shown)

On this page

  • Synopsis

Trials

  • Clinical trials
  • About this drug

Physicians

  • Physician Buzz
Similar Products
medicine
Imcivree
medicine
Slimming Patch
medicine
OB Metab
medicine
Zepbound
Synopsis
Generated with AlphaAI
Product:
Cagrilintide
Category:
Indication:
Mechanism:
Safety:
Dosing:
Patient:
Reviews:
No reviews yet
see more
Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

Clinical trials (7)

NCTPhaseStatusSponsorPrimary Completion
NCT06780449Phase 3ACTIVE_NOT_RECRUITINGNovo Nordisk A/SAug 28, 2028
NCT07220642Phase 3ACTIVE_NOT_RECRUITINGNovo Nordisk A/SMay 11, 2027
Status: Investigational
Tested in peopleEvidence: Tested in peopleTested in at least one proper controlled study in people, with results.
NCT07253285
Phase 3
RECRUITING
Novo Nordisk A/S
Mar 20, 2030
NCT07745504Phase 3RECRUITINGNovo Nordisk A/SMay 18, 2027
NCT05669755Phase 3ACTIVE_NOT_RECRUITINGNovo Nordisk A/SSep 1, 2027
NCT07220759Phase 3ACTIVE_NOT_RECRUITINGNovo Nordisk A/SMay 12, 2027
NCT05567796Phase 3ACTIVE_NOT_RECRUITINGNovo Nordisk A/SOct 30, 2024

About this drug

Status
Active in clinical trials
Last Refreshed
Nov 13, 2026

Physician Buzz

Pre-Approval Insights

Be the First to Share Your Perspective

Share your pre-launch perspective on Cagrilintide and help peers make informed prescribing decisions.

Your 45-second perspective helps thousands of colleagues.

Help Peers Make Better Decisions

Your real-world insights guide colleagues

Anonymous to Pharmaceutical Companies

Your identity stays private — only specialty/region shown

See Peer Benchmarks

Compare your perspective to specialty peers

There isn't any reviews posted yet. You can be the first to review the product